Democrats Flag Trump Drug Stocks, White House Pushes Back

Congressional Democrats released a report Friday saying investments made on behalf of President Donald Trump in pharmaceutical companies rose from a maximum reported value of $1.7 million in 2024 to as much as $56.2 million by the end of 2025. The White House calls it a manufactured controversy. Still, the figures are drawing scrutiny.

The report came from the minority arm of the Joint Economic Committee, led by Democratic Sen. Maggie Hassan. It says as much as $39.1 million of the holdings are in companies that benefited from exemptions created by a provision in Republicans’ 2025 tax and spending law.

What the Report Alleges

Committee Democrats say they dug further into Trump’s financial disclosures. They found that his portfolio bought as much as $2.55 million in shares of drug companies benefiting from the exemptions on three dates before he signed the legislation in July 2025. That included as much as $950,000 in purchases on July 1, 2025, the day the Senate passed the bill. In August 2025, after the bill became law, the portfolio bought as much as $1 million in AbbVie stock.

The buying continued. The report says the portfolio traded pharmaceutical stocks during the first eight months of 2026, adding as much as $3.5 million in stock wealth in the sector.

Hassan called the findings “outrageous and yet typical from this president, who makes the American people foot the bill again and again for his own gains.”

The White House Response

The administration rejects the premise. White House spokesperson Davis Ingle said third-party financial institutions independently manage Trump’s stock and bond portfolio, and denied any conflict of interest. “Neither President Trump nor any member of his family has any ability to direct, influence, or provide input regarding how the portfolio is invested or when investments are bought or sold,” Ingle said.

The White House has repeatedly denied ethics issues and accused Democrats of “attempts to fabricate conflicts of interest.”

That distinction matters. The report documents trades and their timing, but it doesn’t show, based on the facts presented, that anyone in Trump’s orbit directed them. Third-party portfolio management is a standard arrangement for officials with large holdings, designed to separate policy decisions from investment decisions.

The Policy at Issue

The policy fight behind the report deserves a look on its own. A law passed under President Joe Biden’s Democratic administration allowed Medicare to negotiate prices for some of the costliest prescription drugs for the first time. Republicans’ 2025 tax and spending bill expanded an existing exemption for drugs developed to treat rare diseases or conditions. Healthcare research nonprofit KFF says the change delayed when certain costly drugs could become eligible for negotiation or excluded them entirely.

Supporters argued that the broader exemption, known as the orphan drug exclusion, would encourage development of rare-disease treatments. Critics said it lets makers of blockbuster drugs avoid negotiations that could lower costs for Medicare and its recipients.

The report estimated that Medicare beneficiaries receiving Keytruda, made by Merck, and Opdivo, made by Bristol Myers Squibb, could pay roughly $5,000 more annually than they would if Medicare negotiated prices for the drugs. Trump’s portfolio includes stock in both companies.

The findings come as Trump has made lowering prescription drug costs a central part of his healthcare policy. His administration struck deals with pharmaceutical companies that it said would make medications more affordable. Drug pricing, as the underlying coverage notes, rests on a complicated set of factors.

Polling by The Associated Press-NORC Center for Public Affairs Research found most Americans think Trump is profiting from the presidency in unethical or illegal ways and is more focused on his wealth than on helping people like them.

Why This Matters:

Two questions are tangled together here, and voters deserve to see them separately. The first is whether the orphan drug exclusion is sound policy: supporters say it spurs rare-disease research, while critics say it shields blockbuster drugs from price negotiation. That’s a legitimate debate over incentives and costs, and it’ll shape what Medicare beneficiaries pay. The second is whether the president’s portfolio creates a conflict. The report documents the timing and size of trades, but the White House says an independent third party makes those calls. Public trust in markets and institutions depends on clear, enforceable separation between officials’ finances and their policy decisions. When that line looks blurry, even a defensible policy can lose credibility. Lawmakers from both parties have reason to want transparent rules.